Acrivon Therapeutics, Inc.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — |
| Operating Expenses | ||||||
| Research & Development | — | $60.0M | $64.0M | $46.0M | $23.9M | — |
| SG&A Expense | — | $24.1M | $25.2M | $21.1M | $8.7M | — |
| Operating Income | — | $-84.1M | $-89.2M | $-67.1M | $-32.7M | $-16.2M |
| Operating Margin | — | — | — | — | — | — |
| Interest Expense | — | — | — | — | — | — |
| Pretax Income | — | $-77.8M | $-80.4M | — | — | — |
| Income Tax Expense | — | $0 | — | — | — | — |
| Net Income | — | $-77.9M | $-80.6M | $-60.4M | $-31.2M | $-16.2M |
| Net Margin | — | — | — | — | — | — |
| EPS (Basic) | — | $-2.02 | $-2.38 | $-2.74 | $-1.51 | $-0.93 |
| EPS (Diluted) | — | $-2.02 | $-2.38 | $-2.74 | $-1.51 | $-0.93 |
| Shares Outstanding (Basic) | 38.7M | 38.5M | 33.8M | 22.1M | 20.6M | 17.4M |
| Shares Outstanding (Diluted) | 38.7M | 38.5M | 33.8M | 22.1M | 20.6M | 17.4M |
| Dividends Per Share | — | — | — | — | — | — |